BIONtech breaks ground for manufacturing site in Rwanda
BioNtech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this years end toKigall.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 682 entries already.
Entries by Thomas Gabrielczyk
Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
/in News/by Thomas GabrielczykIn an effort to become a major player in Europes growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.
French ImCheck get´s a USD103m check by Pfizer and a pack of VCs
/in News/by Thomas GabrielczykImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The […]
$50m for London CHARM Therapeutics for deep minded folding expertise
/in News/by Thomas GabrielczykCHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology.
Biotalys first proteinbased biocontrol shows up in vineyards
/in News/by Thomas GabrielczykBased on data from the latest trials in grapes across vineyards in diverse climates throughout California and New York, Biotalys’ biocontrol product Evoca provided superior preventative control of Botrytis bunch rot in grapevines compared to chemical standard. Approval is estimated within this year.
Andera Partners co-leads $118m Series B of Mineralys thx (USA)
/in News/by Thomas GabrielczykAndera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.
From waste to sugar – demonstration plant opens in Wales
/in News/by Thomas GabrielczykThe South Wales-based demonstration plant "VAMOS" that generates industrial biotechnology sugars and other recycled material streams from the paper and card in mixed household waste has come online these days. The products will be used in the production of several high-performance bio-based materials.
International Vaccine Institute IVI will locate its European office in Stockholm
/in News/by Thomas GabrielczykThe International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.
Abliva decides on a SEK200m financing to fund Phase 2/3 study
/in News/by Thomas GabrielczykThe financing (around 19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
Transine Therapeutics Ltd closes £13.7m seed financing
/in News/by Thomas GabrielczykTransine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF.